Please assess the completion status of the following clinical trial:

Trial Title: Dulce Digital-COVID Aware (DD-CA) Discharge Texting Platform for US/Mexico Border Hispanics With Diabetes + COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Are a patient admitted to a Scripps Mercy Hospital,~* Consider yourself Hispanic/Latino, of any race~* Are 18 years of age or older,~* Speak English or Spanish,~* Have type 2 diabetes and A1c ≥ 7% in the last 90 days, and~* Have a cellphone that can receive/send text messages.~Exclusion Criteria:~* Are pregnant,~* Are currently participating in another diabetes or COVID-19 related study, or~* Do not meet all eligibility inclusion criteria.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DD-CA (Type: EXPERIMENTAL): In the DD-CA arm, participants will be offered a proven digital texting platform in their language of preference (Spanish/English) as part of the diabetes transitions discharge program with added COVID support messages.
- Usual Care (UC) (Type: ACTIVE_COMPARATOR): UC participants will not receive the added COVID support messages, both arms will have a referral placed to the Diabetes Transitions Service (DTS) as part of usual care at the time of discharge.

Based on this trial design, predict the completion outcome and termination type (if applicable).